Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

July 31st 2025

Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025

Older regimens for CLL were frequently used in older patients and were associated with significantly shorter overall survival, the authors found. | image credit: Saiful52 - stock.adobe.com
Newer Agents Should Be Used in First Line for Older Patients With CLL

July 28th 2025

Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg
Exercise Tied to Improved Symptoms, QOL in Patients With CLL

July 27th 2025

More News

Red blood cells | Image credit: wanchalerm – stock.adobe.com
January 31st 2025

Targeted Therapy in CLL May Impact Blood Cell Behavior

Hayden E. Klein
Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.
John Burke, MD | Image credit: Navigating Cancer
January 22nd 2025

John Burke, MD, Discusses Survey on Venetoclax Uptake Among Community Physicians

Mary Caffrey John Burke, MD
Chromosomes with Telomere floating on blue background | Image credit: peterschreiber.media – stock.adobe.com
January 21st 2025

Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL

Jared Kaltwasser
New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL).
chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com
January 15th 2025

BTKi Resistance Mechanisms, Solutions Probed at ASH

Jared Kaltwasser
One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.
Ibrutinib packaging | Image credit: CLShebley – stock.adobe.com
January 10th 2025

Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show

Karen Jacobson-Sive
The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Patient with leukemia receiving treatment | Image credit: tonefotografia – stock.adobe.com
January 8th 2025

Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024

Gayle Turim Dickstein
Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.
New Generation of CAR T May Elicit Improved CR Rates in CLL
January 3rd 2025

New Generation of CAR T May Elicit Improved CR Rates in CLL

AJMC Contributor
A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Mehrdad Mobasher, MD, MPH | Image credit: BeiGene
January 2nd 2025

BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024

Mary Caffrey
This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change January 2, 2025.
Top 5 CLL of 2024
December 26th 2024

Top 5 Most-Read CLL/SLL Articles of 2024

Christina Mattina
This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.
A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com
December 19th 2024

Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease

Karen Jacobson-Sive
Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
doctor and patient - Sebra - stock.adobe.com.jpg
December 16th 2024

Different Bruton Tyrosine Kinase Inhibitors Bring Distinct Changes to Full-Length BTK

Jared Kaltwasser
The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.
CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Guidelines folder-tashatuvango-stock.adobe.com.jpeg
December 2nd 2024

New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia

Karen Jacobson-Sive
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.
New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com
November 29th 2024

Tattoos May Be Associated With Increased Risk of Rare NHLs

AJMC Contributor
Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.
Big Data | Image Credit: © Friends Stock-stock.adobe.com
November 26th 2024

Real-World Data Confirm Ibrutinib's Role in Relapsed CLL

Gayle Turim Dickstein
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com
November 23rd 2024

Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles

Jared Kaltwasser
The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).
CLL over the image of a stethoscope and red blood cells | Image credit: Saiful52 - stock.adobe.com
November 21st 2024

Treating Double-Exposed Patients With CLL: A Continued Unmet Need

Gayle Turim Dickstein
For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps
Health care costs and fees | Image Credit: © everythingpossible - stock.adobe.com
November 9th 2024

Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World

AJMC Contributor
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.
NK Cell test | Image Credit: © jarun011-stock.adobe.com
November 6th 2024

KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment

AJMC Contributor
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment.
Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com
November 2nd 2024

Review Emphasizes Potential Infection Risks With BTK Inhibitors

Gayle Turim Dickstein
Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com
October 30th 2024

Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL

Karen Jacobson-Sive
The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com
October 23rd 2024

Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients

Kimberly Rath, PharmD
A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy.
money and stethoscope | Image Credit: © pla2na - stock.adobe.com
October 17th 2024

Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL

AJMC Contributor
The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.
Skin Cancer Potential | Image Credit: © Monstar Studio-stock.adobe.com
October 16th 2024

Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis

Karen Jacobson-Sive
Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.
Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com
October 9th 2024

Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL

Jared Kaltwasser
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.
diagnosis leukemia | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com
October 4th 2024

Real-World Data Support TKI Discontinuation After CP-CML Remission

Jared Kaltwasser
Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.
CAR T cell | Image Credit: © Christoph Burgstedt - stock.adobe.com
October 3rd 2024

B-Cell Activating Factor Receptor CAR T Therapy Holds Promise for CLL

Karen Jacobson-Sive
B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines.
Clinical research | Image Credit: © peshkova-stock.adobe.com
September 27th 2024

Venetoclax Plus Rituximab Supports Immune Recovery in CLL

Kimberly Rath, PharmD
Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.
Understanding genetic alterations in CLL could improve personalized medicine strategies | image credit: Shuo - stock.adobe.com
September 24th 2024

Exploring the Impact of TP53 Alterations on miR-34a and NOTCH1 in CLL

Kimberly Rath, PharmD
New study provides insights into the relationship between TP53, miR-34a, and NOTCH1 in CLL cells.
Doctor consulting with a patient | Image Credit: © bnenin - stock.adobe.com
September 19th 2024

Gaps Apparent in Physicians’ Knowledge of CLL, MCL

Nameera Temkar, MD
Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo